Skip to main content

Table 3 Antimicrobial susceptibility among Gram negative isolates including ESBL-producing strains from blood specimens collected between 2012 and 2016

From: Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial

 

Africa

Asia

Europe

North America

Latin America

Global

Global

S%

S%

S%

S%

S%

MIC90(mg/L)

MIC range(mg/L)

S%

R%

MIC90(mg/L)

MIC range(mg/L)

S%

R%

 

E.coli

E.coli, all isolates

E.coli ESBL isolates

N = 47

N = 396

N = 3235

N = 1487

N = 187

N = 5352

N = 852

Amikacin

97.9

97.7

99.5

99.9

98.9

4

0.5–128

99.4

0.2

8

0.5–64

98.4

0.2

Amoxy/clav

48.9

72.0

70.1

78.1

64.7

32

0.25–64

72.1

10.1

32

0.5–64

48.6

14.4

Ampicillin

12.8

18.4

32.8

43.4

26.2

64

0.5–64

34.3

65.0

64

1–64

0.6

99.4

Cefepime

57.5

59.6

82.0

88.8

73.8

16

0.5–64

81.8

13.1

64

0.5–64

13.9

64.7

Ceftazidime

63.8

70.0

86.5

91.6

79.1

8

1–32

86.3

9.4

32

1–32

35.3

42.7

Ceftriaxone

48.9

49.8

78.8

87.4

67.4

64

0.06–64

78.4

21.0

64

0.06–64

0.9

97.8

Levofloxacin

51.1

48.0

64.9

71.6

58.8

16

0.008–16

65.2

31.9

16

0.008–16

16.3

78.9

Meropenem

95.7

98.2

99.9

99.7

97.3

0.06

0.06–32

99.6

0.4

0.12

0.06–16

99.5

0.4

Minocycline

74.5

83.3

85.9

91.3

81.8

8

0.5–32

87.0

7.4

8

0.5–32

86.0

7.3

Pip/taz

80.9

95.0

92.7

97.4

94.4

8

0.06–256

94.1

3.2

16

0.06–256

91.2

4.5

Tigecycline

100

100

99.9

99.9

100

0.25

0.008–16

99.9

0.04

0.5

0.008–2

100

0.0

 

K.pneumoniae

K.pneumoniae, all isolates

K.pneumoniae ESBL isolates

N = 52

N = 276

N = 1761

N = 899

N = 166

N = 3154

N = 659

Amikacin

84.6

90.2

96.7

99.4

96.4

8

0.5–128

96.7

1.8

16

0.5–128

95.8

2.7

Amoxy/clav

25.0

66.7

60.8

90.9

59.0

64

0.12–64

69.2

18.8

64

2–64

19.6

40.2

Ampicillin

1.8

2.2

2.6

6.2

1.2

64

0.5–64

3.5

85.1

64

16–64

0

99.9

Cefepime

34.6

66.7

65.0

93.3

57.2

64

0.5–64

72.3

23.4

64

0.5–64

8.4

78.0

Ceftazidime

34.6

69.2

67.0

91.2

68.7

32

1–32

73.6

21.7

32

1–32

18.1

65.0

Ceftriaxone

21.2

62.7

62.5

90.6

54.2

64

0.06–64

69.4

29.8

64

0.06–64

1.8

97.3

Levofloxacin

57.7

76.5

70.8

91.4

80.7

16

0.008–16

77.5

18.7

16

0.03–16

40.5

47.7

Meropenem

84.6

89.5

87.9

98.0

91.6

1

0.06–32

91.1

8.0

8

0.06–32

84.8

11.7

Minocycline

71.2

83.3

78.6

87.5

83.7

16

0.5–32

81.7

11.5

16

0.5–32

70.3

18.2

Pip/taz

55.8

80.8

76.7

94.1

77.1

256

0.06–256

81.7

15.0

256

0.5–256

59.6

29.1

Tigecycline

96.2

93.1

94.4

95.6

97.6

2

0.008–16

94.8

0.7

2

0.008–16

90.4

1.2

 

S.marcescens

 

N = 29

N = 88

N = 591

N = 224

N = 92

N = 1024

 

Amikacin

100.0

96.6

99.0

100.0

85.9

4

0.5–128

97.9

0.9

    

Amoxy/clav

0.0

8.0

3.1

1.3

3.3

64

0.5–64

3.0

92.4

    

Ampicillin

0.0

6.8

6.3

4.0

4.4

64

0.5–64

5.5

87.3

    

Cefepime

89.7

85.2

96.6

98.7

80.4

1

0.5–64

94.4

3.8

    

Ceftazidime

96.6

88.6

96.1

98.2

87.0

2

1–32

95.1

3.8

    

Ceftriaxone

89.7

79.6

85.3

88.0

71.7

4

0.06–64

84.3

11.8

    

Levofloxacin

100.0

94.3

95.8

96.0

89.1

1

0.008–16

95.2

2.9

    

Meropenem

96.6

95.5

99.0

99.1

93.5

0.25

0.06–32

98.1

1.6

    

Minocycline

100.0

88.6

90.4

94.2

88.0

4

0.5–32

91.9

2.3

    

Pip/taz

100.0

89.8

94.1

97.3

90.2

8

0.06–256

94.2

2.4

    

Tigecycline

96.6

95.5

97.0

97.8

93.5

2

0.03–16

96.7

0.3

    
 

E.cloacae

 

N = 47

N = 157

N = 1084

N = 404

N = 132

N = 1824

 

Amikacin

95.7

96.8

99.0

100.0

97.0

4

0.5–128

98.8

0.9

    

Amoxy/clav

2.1

1.9

3.7

3.0

1.5

64

0.12–64

3.2

95.4

    

Ampicillin

4.3

3.2

6.8

4.5

4.6

64

0.5–64

5.8

89.5

    

Cefepime

51.1

76.4

77.2

86.9

74.2

16

0.5–64

78.4

12.0

    

Ceftazidime

51.1

63.1

65.0

74.5

65.9

32

1–32

66.7

29.6

    

Ceftriaxone

40.4

59.2

59.7

70.5

60.6

64

0.06–64

61.6

36.2

    

Levofloxacin

91.5

87.9

85.8

94.6

86.4

4

0.008–16

88.1

9.8

    

Meropenem

100.0

94.3

97.2

99.5

97.7

0.25

0.06–32

97.6

1.6

    

Minocycline

85.1

84.1

86.0

86.9

88.6

8

0.5–32

86.2

8.2

    

Pip/taz

78.7

75.2

76.3

81.7

79.6

128

0.06–256

77.7

11.5

    

Tigecycline

95.7

96.8

95.4

95.5

97.0

2

0.008–16

95.7

0.8

    
 

P.aeruginosa

 

N = 29

N = 150

N = 1081

N = 387

N = 95

N = 1739

    

Amikacin

96.6

95.3

94.3

97.9

88.4

8

0.5–128

94.9

2.7

    

Cefepime

65.5

76.0

75.5

86.3

85.3

16

0.5–64

78.4

9.1

    

Ceftazidime

79.3

77.3

78.8

88.9

82.1

32

1–32

81.1

11.4

    

Levofloxacin

86.2

82.7

72.4

76.5

75.8

16

0.015–16

74.6

19.8

    

Meropenem

75.9

69.3

69.6

75.7

69.5

16

0.06–32

71.1

22.0

    

Pip/taz

82.8

78.0

78.3

86.8

85.3

64

0.12–256

80.7

7.9

    
 

A.baumannii

    

N = 32

N = 123

N = 424

N = 118

N = 52

N = 749

    

Amikacin

31.3

43.1

37.0

74.6

28.9

128

0.5–128

43.1

49.1

    

Cefepime

12.5

27.6

24.1

54.2

15.4

64

0.5–64

28.3

65.7

    

Ceftazidime

15.6

35.0

27.1

50.0

23.1

32

1–32

31.2

64.2

    

Ceftriaxone

9.4

22.8

16.0

31.4

11.5

64

0.06–64

19.0

67.0

    

Levofloxacin

21.9

30.9

23.6

51.7

15.4

16

0.008–16

28.6

61.7

    

Meropenem

25.0

26.8

26.9

60.2

15.4

32

0.06–32

31.2

66.8

    

Minocycline

81.3

73.2

61.8

89.0

90.4

8

0.5–32

70.8

8.8

    

Pip/taz

12.5

26.0

24.5

52.5

13.5

256

0.06–256

27.9

68.2

    

Tigecycline

     

2

0.008–4

      
  1. Abbreviations: S% percentage of susceptible isolates, R% percentage of resistant isolates, MIC minimum inhibitory concentration, Amoxy/clav Amoxicillin/clavulanic acid, Pip/taz Piperacillin/tazobactam